Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.

ABSTRACT:

Aims

To determine whether thiazolidinedione use is associated with a risk of bladder cancer.

Methods

We searched MEDLINE and EMBASE in June 2012 (with PubMed update to July 2013) and conducted meta-analysis on the overall risks of bladder cancer with pioglitazone or rosiglitazone and the risk with different categories of cumulative dose or duration of drug use.

Results

We screened 230 citations and included 18 studies, comprising five randomized controlled trials (RCTs) and 13 observational studies. Meta-analysis showed a significantly higher overall risk of bladder cancer with pioglitazone in RCTs [7878 participants; odds ratio (OR) 2.51, 95% confidence interval (CI) 1.09-5.80] and observational studies (>2.6 million patients; OR for 'ever' users vs. non-users 1.21,

SUBMITTER: Turner RM 

PROVIDER: S-EPMC4137819 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature